Regorafenib and Sintilimab in Combination with Electroacupuncture in MSS CRC

NARecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

May 1, 2024

Primary Completion Date

March 31, 2026

Study Completion Date

March 31, 2026

Conditions
Colorectal Cancer Metastatic
Interventions
DRUG

Regorafenib and Sintilimab in combination with electroacupuncture

Regorafenib, take for 2 weeks and stop for 1 week; Sintilimab, intravenous, every 3 weeks; Electroacupuncture was performed 1 day before, on the day of, and on the 2nd day after each cycle of Sintilimab administration, and patients completed 3 treatments in week 1, followed by 1 treatment per week for 2 weeks, with 5 treatments per dosing cycle.

Trial Locations (1)

Unknown

RECRUITING

The First People's Hospital of Changzhou, Changzhou

All Listed Sponsors
lead

The First People's Hospital of Changzhou

OTHER